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Abstract 
Background/Aim: Perfluoroalkyl substances (PFASs) are chemical compounds used in consumer 
products and are linked with increase in cholesterol, thyroid disease, and pregnancy-induced 
hypertension. However, their association with lung function is not completely understood.  
Methods: Cross sectional 2011-12 U.S. population data from the National Health and Nutrition 
Examination Survey (NHANES) was used (N=1,450, aged 12 to 79 years, 52% men). Serum 
concentration of four PFASs, perfluorononanoic acid (PFNA), perfluorooctanoic acid (PFOA), 
perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS) were assessed 
using mass spectrometry and were categorized into tertiles. Lung function was measured by 
spirometry as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and 
the ratio of FVC/FEV1 (%). Sex stratified adjusted linear regression analysis was used to predict 
lung function with PFASs tertiles.  
Results: In men all four PFASs serum concentrations and lung function was higher, except 
FVC/FEV1 (%) which was lower than women (p<.001 for all). In men, compared with low 
tertiles, high exposure to PFOS, PFNA, predicted a significant decrease in FEV1 and FVC, 
respectively, and PFOA, PFOS, and PFHxS predicted significant low FVC/FEV1 (%) in 
unadjusted models. In women, compared with low tertiles, high exposure to all PFASs predicted 
a significant decrease in FEV1, FVC and FVC/FEV1 (%) (except PFHxS in FVC), respectively, 
in unadjusted models (p<.001). No association was seen in adjusted models in both men and 
women.  
Conclusion: High PFASs exposure has a consistent significant negative impact on female lung 
function in unadjusted analysis and this association needs further exploration.  
 Keywords: Perfluoroalkyl Substances, PFAS, NHANES, Public Health, Lung Function 
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The Association of Perfluoroalkyl Substance Exposure and Lung Function in the U.S. 
Population 
Chemical exposures are a relevant public health concern due to the vast amount of 
chemicals in the environment to which the public is exposed, often with unknown side effects. 
Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are a group of chemicals that can be 
found in carpets, clothing, food packaging, firefighting foam, and non-stick cookware coatings 
(Pérez et al., 2013; Kirk et al., 2018; Timmermann et al., 2017). These chemicals are widely used 
in common consumer products due to their hydrophobic, to water repellant, and lipophobic, 
insoluble in fat, natures (Pérez et al., 2013; Kirk et al., 2018). PFASs have a high chemical and 
thermal stability (Qin et al., 2017) meaning that they are less likely to break down in normal day-
to-day conditions. This stability allows industries to use PFASs in the many consumer products. 
Once absorbed through inhalation, oral or dermal routes, PFASs have been found to accumulate 
in multiple tissues in humans, including the lungs (Pérez et al., 2013). PFASs have also been 
found to cause an increase in cholesterol, increase the risk of a thyroid disease, decreased fertility 
and pregnancy-induced hypertension in humans (Agency for Toxic Substances and Disease 
Registry [ATSDR], 2018a; ATSDR, 2018b). 
The lungs are one of the main tissues that accumulate PFASs after exposure (Pérez et al., 
2013) and yet little research has been done regarding lung function and outcomes with PFAS 
exposure. There has been scant research on the association between exposures to PFASs and 
lung function in the human population; most of the research has been on animal populations. In a 
study conducted by Timmermann et al. (2017), PFASs exposure and asthma in children were 
found to have a lower vaccine antibody response to measles, mumps and rubella (MMR) 
vaccination. Children with an increased serum concentration of PFAS had higher odds of history 
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of asthma in unvaccinated children compared to those who were vaccinated. A study on the 
exposure of PFASs and children found that there is an association between PFASs and impaired 
lung function (Qin et al., 2017).  
More research has been conducted on animals involving PFASs and lung functions. 
Studies have found that PFASs negatively impact the development of mammals, resulting in 
lower birth weight and neonatal mortality. Research has demonstrated that the neonatal mortality 
in animals was caused by under-developed lungs and the failure of lung function (Ye et al., 
2012). Other outcomes associated with PFAS and lungs include an increase in the 
immunoglobulin IgE, which is associated with allergy response (Qin et al., 2017; Timmermann 
et al., 2017) and an increase in airway inflammation and altered airway function in animal 
models (Qin et al., 2017). Given the limited amount of evidence found in the animal models 
involving the negative impact of PFASs on lung function, it is important to explore if the same is 
true in human population.  
The burdens of lung function disease, such as chronic obstructive pulmonary disease 
(COPD), and asthma, have become more prominent in the United States (U.S.) (Cukic, Lovre, 
Dragisic, & Ustamujic, 2012). COPD is characterized by the limitation of airflow in the lungs 
(Carey et al., 2007). COPD is more prevalent in males than females, mainly due to the smoking 
rate in males being higher than in females (Carey et al., 2007; LoMauro & Aliverti, 2018). 
However, females develop COPD earlier than males due to the smaller lung capacity, creating a 
faster decline in lung function (LoMauro & Aliverti, 2018). Asthma is more prevalent among 
females than males in the general population (Carey et al., 2007; LoMauro & Aliverti, 2018), 
although the prevalence and severity changes with age (Carey et al., 2007). Likewise, in 
children, asthma incidence is more frequent in males (LoMauro & Aliverti, 2018).  
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Statement of Purpose 
The objective of this project is to determine what types of association PFASs exposure 
have with lung function among the U.S. population. Using the National Health and Nutrition 
Examination Survey (NHANES) 2011 to 2012, we hypothesized that increasing serum levels of 
PFASs, specifically perfluorononanoic acid (PFNA), perfluorooctanoic acid (PFOA), 
perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS), in the U.S. 
population would be associated with decreased lung function, as assessed by spirometry, and will 
differ by gender. 
Literature Review 
Perfluoroalkyl and Polyfluoroalkyl Substances 
 PFASs are a group of chemicals that consist of hundreds of different types, but only 
about twelve are commonly found and studied (Rodriguez-Jorquera & Toor, 2015; ATSDR, 
2018b). PFASs are chemicals that have a high thermal and chemical stability (Qin et al., 2017). 
PFASs are made up of a carbon backbone, which can vary from a length of four carbons to 
twelve carbons, with fluorine substitutions (ATSDR, 2018c) (see Figure 1). These carbon-
fluorine bonds provide strength giving the thermal and chemical stability that allows the 
chemicals to be resistant to break down (Pérez et al., 2013). PFASs have a ‘head’ and a ‘tail’ 
(Figure 1). The ‘head’ and ‘tail’ can vary based on which PFAS chemical is being examined, due 
to different molecular structures which affects the charge of the ‘head’. In a review published by 
Kirk and colleagues (2018), the ‘head’ of the PFAS molecule was found to regulate where in the 
body that the PFAS would accumulate. 
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Figure 1. PFNA molecule structure. Made using MolView (Bergwerf, 2015). 
PFASs also have a hydrophobic and lipophobic nature (Pérez et al., 2013; Kirk et al., 
2018). Hydrophobic is a term used when referring to substances that are able to repel water, and 
lipophobic is a term used when referring to substances that are not soluble in lipids or non-polar 
solvents, such as fats. Due to these properties, PFASs are widely used in manufacturing products. 
 PFASs bind to serum proteins with high affinity. PFASs especially bind to albumin, 
which acts as a transporter of insoluble molecules, because of the high affinity between the 
receptor and its ligand (Kirk et al., 2018). PFASs bioaccumulate in the body, meaning that they 
become concentrated inside the body due to the fact that the rate at which the body absorbs 
PFASs is faster than what the body can excrete or catabolize. Perfluoroalkyl substances are 
excreted mostly through the renal system (ATSDR, 2018b; Pérez et al., 2013). A study by Pérez 
et al. (2013), found that PFASs have the highest accumulation in lung tissues. Liver and brain 
tissue were also found to accumulate PFASs.  
Exposures to PFASs 
 There are many ways that humans can be exposed to PFAS. Some of the products that 
contain PFASs include food packaging, firefighting foam, non-stick cookware, photographic 
films and furniture (Pérez et al., 2013; Kirk et al., 2018; Timmermann et al., 2017). There are 
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three exposure routes into the body; the oral route into the body is the most rapid and the most 
common form of exposure for the general population. The dermal route is possible but less 
likely; however, it could be an exposure route for those occupational workers who handle 
products with PFAS (Rodriguez-Jorquera & Toor, 2015; ATSDR, 2018b). The inhalation route 
has not been studied enough in epidemiological studies, but is considered the most common form 
of exposure route for the occupational workers (Rodriguez-Jorquera & Toor, 2015; ATSDR, 
2018b).  
 PFAS exposure could also occur through contaminated water, soil, air, and food. The 
industries that manufacture products release PFASs into the surrounding air or the surface water 
around the industrial plant (ATSDR, 2018b; ATSDR, 2018c). Manufacturing of some PFAS 
products in the U.S. has been phased out since the early 2000’s (ATSDR, 2018c). PFAS still 
remain present in the environment due to their resistance to break down. Thus, they seep into the 
ground-water, and they persist in the soil. Wind and rain are able to carry the chemicals great 
distances, spreading the exposure radius to places where there are no manufacturing plants 
(ATSDR, 2018a; ATSDR, 2018b).  
Health Effects 
 Several health effects have been associated with PFAS exposures. The main health 
effects associated with humans are increased cholesterol, an increased risk of thyroid disease and 
a decrease in female fertility (ATSDR, 2018a; ATSDR, 2018b). Pregnant woman are also 
affected by PFAS exposure; they have an increased chance of high blood pressure, pre-eclampsia 
and lower birth weight in infants (ASTDR, 2018a).  
 Animal studies have been conducted to help determine the health effects caused by 
PFASs exposure. Some of the main health effects found in animal studies have been liver 
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damage, immune toxicity, and cancer of the liver, pancreas and reproductive organs (ASTDR, 
2018b; Rodriguez-Jorquera & Toor, 2015). Animal studies on PFASs have also been found to 
impact birth outcomes, such as delayed development, increased birth defects, reduced birth 
weight and a reduced number of live births (ATSDR, 2018a; Rodriguez-Jorquera & Toor, 2015). 
Respiratory health effects. Few studies have been conducted on the respiratory effects 
of PFASs on humans. There are, however, a few studies that demonstrate that PFASs have some 
impact on the respiratory system. In a study conducted by Timmermann et al. (2017), PFASs 
exposure and asthma in children were found to have a lower vaccine antibody response to the 
MMR vaccination. Children with an increased serum concentration of PFAS had higher odds of 
history of asthma in unvaccinated children compared to those who were vaccinated. Another 
study conducted by Qin et al. (2017) found an association between PFAS exposure and impaired 
lung function in children. The lungs are one of the main tissues in which PFASs accumulate 
(Pérez et al., 2013). 
 More studies have been done on animals to test the respiratory effects caused by PFASs. 
In a study by Ye et al. (2012), PFAS exposure caused neonatal mortality in mice, which was 
caused by under-developed lungs. Animals exposed to PFAS have also been found to increase 
serum immunoglobulin E (Qin et al., 2017; Timmermann et al., 2017). In a study conducted with 
mice pups, exposure to PFAS were found to cause altered airway function, induced airway 
inflammation and increased the airway response in an allergic murine model (Qin et al., 2017). 
Spirometry 
 Spirometry is a pulmonary function test, also known as a breathing test, which is able to 
analyze overall lung function (Sood, Dawson, Henkle, Hopkins-Price, & Quails, 2007). 
Spirometry is used in testing and surveillance for lung diseases, such as asthma, COPD, chronic 
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bronchitis, emphysema and pulmonary fibrosis (Sood et al., 2007; Coates et al., 2013). The test 
is conducted by measuring the volume of air exhaled by the patient. The volume can either be 
calculated directly, when the patient has exhaled into an expandable chamber, or by measuring 
the air flow and then calculating the volume from the air flow (Coates et al., 2013). Spirometry 
tests are conducted multiple times in one sitting to ensure consistent results. The common 
spirometry measurements include forced vital capacity (FVC), forced expiratory volume (FEV) 
and forced vital capacity divided by forced expiratory volume (FEV/FVC). 
 FVC is the largest amount of air that a patient is able to forcibly exhale after breathing in 
as deep as they can, it is done to calculate the magnitude of restricted breathing (Coates et al., 
2013; Hankinson et al., 2010). The lower the FVC the greater the breathing restriction. Forced 
expiratory volume in one second (FEV1) is used to calculate how much air a patient can force 
from their lungs in one second (Coates et al., 2013; Hankinson et al., 2010). FEV1 calculations 
help determine the severity of breathing problems; see Table 1. A ratio of FEV1 to FVC is 
calculated to determine if the results are normal when compared to reference values (Coates et 
al., 2013). Reference values set for each of these variables based on NHANES III, see Table 1 
(Sood et al., 2007; Hankinson et al., 2010).  
Table 1 
NHANES III Reference Values of Spirometry (FEV1 and FEV1/FVC) 
Degree of Severity   FEV1 % Predicted   FEV1/FVC Ratio 
Normal 
 
~100 
 
.70-.80 
Mild 
 
>70 
 
<.70 
Moderate 
 
60-69 
 
<.70 
Moderately Severe 
 
50-59 
 
<.70 
Severe 
 
35-49 
 
<.70 
Very Severe  <35   <.70 
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Methods 
Data Source and Study Sample 
This was a cross sectional study using existing data from NHANES 2011 to 2012 from 
healthy individuals (N = 1,450; 12 years through 79 years old; 752 men and 698 women) to 
evaluate the association between PFASs and lung function measured by spirometry (FEV1, FVC, 
and FEV1/FVC). NHANES is a population-based survey conducted on individuals within the 
U.S. population in assigned subgroups focusing on specific diseases and risk factors. The total 
number of individuals who were interviewed in the 2011 to 2012 NHANES was 9,756 and 9,338 
of those individuals were examined (Centers for Disease Control and Prevention, National 
Center for Health Statistics [CDC NCHS], 2018). These participants are examined in a mobile 
examination center (MEC).  
The MEC is used to ensure a standardized examination environment for laboratory 
measurements, physical assessments and examinations. Questionnaires were also used to collect 
demographic and personal information (age, sex, race/ethnicity, income, education, and 
occupation), medical history (current health status and chronic conditions), physical activity, 
alcohol and tobacco use or exposure, and reproductive history. Physical examination included 
measurement of height and weight. The MEC is able to collect biological specimens such as, 
blood, urine, vaginal swabs and oral rinse. All of the MEC laboratory staff complete training to 
learn the standardized NHANES laboratory protocols. All survey materials, consent documents 
and examination information for the NHANES 2011 to 2012 dataset are publicly available on the 
NHANES website as part of the Centers for Disease Control and Prevention (CDC NCHS, 2018; 
CDC NCHS, 2015a; CDC NCHS, 2015b). 
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PFASs Concentration 
 PFASs chemicals, also known as polyfluoroalkyl chemicals (lately PFCs) in NHANES 
2011 to 2012 dataset, were extracted in the blood samples taken in the MEC. The serum from the 
blood samples, a minimum of 0.5mL, is collected and are refrigerated within four hours of 
collection. To test the serum, online solid phase extraction-high performance liquid 
chromatography-turbo ion spray-tandem mass spectrometry (online SPE-HPLC-TIS-MS/MS) 
was used to quantitatively detect PFOA, PFOS, PFNA and PFHxS (CDC NCHS, 2013). The 
serum samples are prepared with 0.1M of formic acid, after being thawed and then inserted in the 
automated SPE-HPLC-TIS-MS/MS. The mass spectrometer is calibrated every three to six 
months and the instrument sensitivity is checked before each test of samples (CDC NCHS, 
2013). The lower limit of detection (LLOD) of each PFAS substance is stated as: PFOA (0.10 
ng/mL), PFOS (0.20 ng/mL), PFNA (0.08 ng/mL), and PFHxS (0.10 ng/mL) (CDC NCHS, 
2014a). If a sample had results below the lower limit of detection the NHANES study designers 
placed an imputed value in the database. This value is calculated by taking the LLOD divided by 
square root of two (LLOD/√2), which can be calculated for each PFAS substance; PFOA (0.07 
ng/mL), PFOS (0.14 ng/mL), PFNA (0.06 ng/mL), and PFHxS (0.07 ng/mL) (CDC NCHS, 
2014a; CDC NCHS, 2013).  
Spirometry Measurement  
 The spirometry measurements were done with the individuals in the MEC. The MEC 
used the Ohio 822/827 dry-rolling seal volume spirometer. Before each test was performed using 
the spirometer, a calibration syringe was used to calibrate the spirometer. Before each test, the 
individuals were asked a series of safety questions (see Appendix A), and if the questions were 
answered positively (“Yes”, “Refused”, or “Don’t Know”) then the individual did not perform a 
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spirometry test (CDC NCHS, 2011). The spirometry was performed by having the individuals 
stand up, unless physically incapable, extend their neck and elevate their chin. A nose clip was 
placed on the nose to prevent any air leaks (CDC NCHS, 2014b). The NHANES examiner had 
the individual take the deepest breath possible so that the lungs would fill with the maximum 
amount of air, and then blow the air out as fast and forcibly as possible. When exhaling into the 
mouthpiece of the spirometer, the individual made sure as to keep their lips around it to create a 
tight seal (CDC NCHS, 2014b). FVC, the maximum volume of air exhaled forcefully after a 
maximal inspiration, was calculated. In an adult (11 to 79 years old), the forced exhalation has a 
minimum of six seconds of exhalation and in children (six to ten years old), the forced exhalation 
has a minimum of three seconds of exhalation (CDC NCHS, 2014b; CDC NCHS, 2011). FEV1, 
the volume of air exhaled during the first second, was calculated (CDC NCHS, 2011). 
Statistical Analysis 
Analyses were performed using the Statistical Package for the Social Science (SPSS) 
(IBM SPSS Statistics for Mac, Version 25.0. Armonk, NY: IBM Corp., 2017). All tests were two 
sided and conducted at the α = .05 level of significance. Analysis was presented for the overall 
data set and also by gender. Descriptive statistics computed for continuous variables included 
measures of centrality (mean, median) and dispersion (standard deviation, range) (age, PFNA, 
PFOA, PFOS, PFHxS, FEV1, FVC and FEV1/FVC). Frequency distributions (number and 
percentage) were examined for categorical variables (race/ethnicity and annual household 
income). Race/ethnicity was recoded from five values into three values: non-Hispanic White 
(reference), non-Hispanic Black, and all others. Annual household income was recoded from 
fourteen values into three values: <$25,000 (reference), $25,000 to <$55,000, and $55,000+ (see 
Appendix B). 
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Chi-square test was used to determine the statistical significance between the categorical 
variables across gender. The statistical significance of associations between the continuous 
variables across gender was tested by an independent-sample t-test for normally distributed 
variables (age, FEV1, FVC, and FEV1/FVC) or by a Mann-Whitney U test for non-normally 
distributed continuous variables (PFNA, PFOA, PFOS, and PFHxS).  
As PFASs were not normally distributed, each individual PFAS was categorized into 
tertiles. Four individual PFASs (exposures/predictor) were tested in each of the lung function test 
(outcome/dependent) analyses (FVC, FEV1, and FEV1/FVC). 
Linear regression analysis was performed to assess association between each PFAS tertile 
separately as predictor (PFNA, PFOA, PFOS, and PFHxS) and the outcome variable (FEV1, 
FVC, or FEV1/FVC). First unadjusted linear models were analyzed, followed by age adjusted 
linear regression and then multivariable regression for other covariates including age, annual 
household income, race/ethnicity. A total of 12 unadjusted linear regressions, 12 age-adjusted 
linear regressions, and 12 multivariable linear regressions were analyzed. Categorical variables 
with more than two levels were dummy coded including, PFAS tertiles, annual household 
income, and ethnicity. Analysis was repeated using continuous log transformed PFASs variables. 
Results 
Descriptive Statistics 
As seen in Table 2, the overall sample of 1,450 NHANES participants, 51.9% were male. 
The mean age of individuals was 39.26 ± 18.85 years. A higher proportion of this group had 
annual household income ≥$55,000. Compared to non-Hispanic White and non-Hispanic Black, 
other races constituted the prevalent group at 39% overall and when comparing males versus 
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females (Table 2). No significant differences between gender was found for age, annual 
household income, and race/ethnicity. 
Table 2 
Characteristics of 2011-2012 NHANES Participants, Overall and by Gender: Male and Female 
 
Male participants had a higher exposure to all four PFASs (0.98, 2.33, 7.96, 1.64 vs 0.81, 
1.73, 4.99, 0.91; all p < .001) respectively, compared to females. Males also had higher 
spirometry measures of FEV1 (3539.49 vs 2628.77; p < .001) and FVC (4475.55 vs 3215.23; p < 
.001) compared to females. However, the reverse was seen in the ratio of FEV1/FVC in which 
female had the highest spirometry measure (81.81 vs 78.98; p = <.001) compared to males, 
respectively. In this sample the overall PFNA value was higher than the national value (CDC 
DHHS, 2019) reported from NHANES 2011 to 2012 (.89 vs .88), as well as PFOS (6.33 vs 
Characteristic Variable Overall N= 1450
   
(51.9%)
   
(48.1%) p-value*
Age (years), mean (SD) 39.26 (18.85) 39.42 (18.96) 39.09 (18.75) .737
Annual Household Income, n .644
<$25,000 427 (29.4) 214 (28.5) 213 (30.5)
$25,000-$54,999 443 (30.6) 230 (30.6) 213 (30.5)
≥$55,000 580 (40.0) 308 (41.0) 272 (39.0)
Race/Ethnicity, n (%) .865
NonHispanic White 497 (34.3) 253 (33.6) 244 (35.0)
NonHispanic Black 386 (26.6) 203 (27.0) 183 (26.2)
All Other 567 (39.1) 296 (39.4) 271 (38.8)
PFNA (ug/L), median (IQR) .89 (.74) .98 (.78) .81 (.64) <.001†
PFOA (ug/L), median (IQR) 2.05 (1.47) 2.33 (1.40) 1.73 (1.34) <.001†
PFOS (ug/L), median (IQR) 6.33 (6.68) 7.96 (7.27) 4.99 (5.27) <.001†
PFHxS (ug/L), median (IQR) 1.22 (1.41) 1.64 (1.60) .91 (.98) <.001†
FEV1 (mL), mean (SD) 3101.09 (880.0) 3539.49 (864.59) 2628.77 (611.33) <.001
FVC (mL), mean (SD) 3868.86 (1058.77) 4475.55 (968.90) 3215.23 (702.84) <.001
FEV1/FVC (%), mean (SD) 80.34 (8.71) 78.98 (8.91) 81.81 (8.25) <.001
*p-values were found by using the chi-square test for categorical variables and a t-test for continuous variables.          
†p-values were found by using the mann-whitney U test for non normal distribution of the continuous variables.          
p-value reports differences between the two categories: Male and Female.
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6.31). The overall PFOA value was lower than the national value (2.05 vs 2.08) as well as 
PFHxS (1.22 vs 1.28). 
Linear Regression Analysis 
In linear regression analysis (Table 3), when compared with low PFOS tertiles, in men, 
high exposure showed a significant decrease in FEV1 in unadjusted models. In unadjusted 
models, with PFNA high exposure showed a negative association with FEV1 (trend towards 
significance, p = .062). In women, all four PFAS’s high exposure tertiles predicted a decrease in 
FEV1 in the unadjusted models (Table 3), additionally the same effect was seen for PFNA for 
medium exposure. However, in neither men nor women, there was no such negative association 
between PFASs and FEV1 seen in age or multivariable adjusted models. In men, almost all 
PFASs in general, except PFNA, showed a significant increase in FEV1 in medium and high 
tertiles, compared to the low tertile, both in the age adjusted and multivariable adjusted models. 
No such association was seen in unadjusted models in men. In the rest of our descriptions of our 
results, only the negative associations of all four PFASs with lung function are presented. 
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Table 3 
Association of PFASs Serum Concentration with FEV1 in NHANES 2011-2012 Participants 
using Unadjusted and Multivariable Adjusted Linear Regression 
 
 
As shown in Table 4, women, when compared with the low tertiles, high exposure in both 
PFOS and PFNA and medium exposure of PFNA showed a significant decrease in FVC in 
unadjusted models. In women, PFNA high exposure predicted a decrease in FVC in the age-
B (95% CI) p-value B (95% CI) p-value
PFOA
Unadjusted                       Med 67.23 (-84.25, 218.71) .384 -33.40 (-144.15, 77.34) .554
High 35.66 (-116.28, 187.60) .645 -149.69 (-260.56, -38.82) .008
Age-adjusted                    Med 108.07 (-24.20, 240.33) .109 47.15 (-41.65, 135.96) .298
High 212.49 (78.02, 346.96) .002 86.30 (-5.26, 177.85) .065
Multivariable-adjusted       Med 83.76 (-41.76, 209.28) .191 -15.82 (-98.61, 66.97) .708
High 181.30 (52.71, 309.89) .006 18.19 (-67.62, 104.00) .677
PFOS
Unadjusted                       Med 135.53 (-13.34, 284.39) .074 -76.68 (-184.96, 21.60) .165
High -190.78 (-341.75, -39.80) .013 -333.91 (-442.31, -225.52) <.001
Age-adjusted                    Med 314.04 (181.67, 446.40) <.001 13.74 (-75.44, 102.92) .762
High 207.85 (65.93, 349.77) .004 2.96 (-92.73, 98.64) .952
Multivariable-adjusted       Med 284.00 (158.51, 409.49) <.001 -30.50 (-113.36, 52.36) .470
High 212.04 (76.79, 347.29) .002 -4.11 (-92.75, 84.53) .927
PFNA
Unadjusted                        Med 35.12 (-115.83, 186.08) .648 -117.68 (-227.24, -8.12) .035
High -144.09 (-295.20, 7.01) .062 -241.86 (-351.54, -132.18) <.001
Age-adjusted                    Med 90.63 (-42.39, 223.65) .181 -28.41 (-117.18, 60.36) .530
High 9.35 (-125.15, 143.85) .891 -56.03 (-146.41, 34.36) .224
Multivariable-adjusted       Med 104.73 (-21.35, 230.81) .103 -22.48 (-104.46, 59.51) .591
High 62.12 (-66.04, 190.28) .342 -32.51 (-116.63, 51.62) .448
PFHxS
Unadjusted                        Med 75.61 (-75.85, 227.07) .327 -39.68 (-150.09, 70.72) .481
High 52.96 (-98.66, 204.57) .493 -186.67 (-296.83, -76.51) .001
Age-adjusted                    Med 159.04 (26.43, 291.65) .019 34.14 (-54.81, 123.09) .451
High 196.41 (62.83, 329.99) .004 11.18 (-79.45, 101.82) .809
Multivariable-adjusted       Med 122.44 (-3.91, 248.80) .058 -8.59 (-91.24, 74.07) .838
High 144.57 (15.52, 273.61) .028 -62.04 (-146.87, 22.80 .152
N = 1450
Male Female
FEV1
*In all models, the reference category was the respective low PFAS tertile.  Med = Medium
Variables that were adjusted for: age, annual household income and race/ethnicity. 
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adjusted model, showing a trend towards significance (p = 0.104). However, in women, no such 
association was seen in multivariable adjusted models for any of the four PFASs. In men, only 
PFNA high exposure showed a significant decrease in FVC in unadjusted models. 
Table 4 
Association of PFASs Serum Concentration with FVC in NHANES 2011-2012 Participants using 
Unadjusted and Multivariable Adjusted Linear Regression 
 
 
B (95% CI) p-value B (95% CI) p-value
PFOA
Unadjusted                        Med 50.63 (-118.96, 220.22) .558 -14.45 (-142.25, 113.36) .824
High 129.61 (-40.49, 299.71) .135 -95.03 (-222.98, 32.91) .145
Age-adjusted                     Med 79.71 (-81.67, 241.10) .333 48.28 (-69.05, 165.60) .419
High 255.53 (91.46, 419.61) .002 88.72 (-32.24, 209.68) .150
Multivariable-adjusted        Med 51.21 (-97.94, 200.36) .500 -49.55 (-154.49, 55.39) .354
High 193.17 (40.37, 345.97) .013 -10.99 (-119.76, 97.79) .843
PFOS
Unadjusted                        Med 232.91 (65.64, 400.18) .006 -53.90 (-179.44, 71.65) .400
High -76.71 (-246.35, 92.93) .375 -315.71 (-441.39, -190.03) <.001
Age-adjusted                     Med 359.78 (197.95, 521.61) <.001 13.01 (-104.55, 130.57) .828
High 206.60 (33.09, 380.11) .020 -66.48 (-192.61, 59.65) .301
Multivariable-adjusted        Med 307.67 (158.25, 457.09) <.001 -59.66 (-164.61, 45.29) .265
High 180.47 (19.43, 341.51) .028 -74.78 (-187.05, 37.49) .191
PFNA
Unadjusted                        Med -15.14 (-184.43, 154.15) .861 -134.43 (-260.81, -8.05) .037
High -173.39 (-342.86, -3.93) .045 -239.92 (-366.44, -113.39) <.001
Age-adjusted                     Med 22.65 (-139.76, 185.07) .784 -66.60 (-183.65, 50.45) .264
High -65.92 (-233.14, 95.30) .410 -98.73 (-217.91, 20.46) .104
Multivariable-adjusted        Med 39.60 (-110.35, 189.56) .604 -56.75 (-160.64, 47.13) .284
High 8.17 (-144.26, 160.60) .916 -50.87 (-157.47, 55.73) .349
PFHxS
Unadjusted                        Med 158.84 (-10.26, 327.94) .066 30.63 (-96.90, 158.16) .637
High 214.11 (44.84, 383,37) .013 115.80 (-243.05, 11.45) .074
Age-adjusted                     Med 218.58 (57.40, 379.76) .008 88.06 (-29.20, 205.32) .141
High 316.83 (154.47, 479.20) <.001 38.12 (-81.37, 157.61) .531
Multivariable-adjusted        Med 146.73 (-3.14, 296.59) .055 16.40 (-88.31, 121.10) .759
High 205.46 (52.41, 358.51) .009 -79.87 (-187.33, 27.59) .145
N = 1450
Male Female
FVC
*In all models, the reference category was the respective low PFAS tertile.  Med = Medium
Variables that were adjusted for: age, annual household income and race/ethnicity. 
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When compared with low PFOA, PFOS, and PFHxS tertiles, in men, high exposure 
showed a decrease in FEV1/FVC in unadjusted models (Table 5) with PFOA trending towards 
significance (p = .086). For women, all four PFASs, in high exposure tertiles predicted decrease 
in FEV1/FVC for unadjusted models, as well as medium exposure of PFHxS. Also in women, 
medium PFHxS exposure showed a decrease in FEV1/FVC in the age-adjusted model, trending 
towards significance (p = .053). However, in neither men nor women, was any such association 
seen in multivariable adjusted models. Results did not change in analysis using continuous log 
transformed PFASs variables. 
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Table 5  
Association of PFASs Serum Concentration with FEV1/FVC in NHANES 2011-2012 
Participants using Unadjusted and Multivariable Adjusted Linear Regression 
 
 
  
B (95% CI) p-value B (95% CI) p-value
PFOA
Unadjusted                        Med 0.62 (-0.93, 2.18) .431 -0.74 (-2.22, 0.75) .331
High -1.37 (-2.93, 0.19) .086 -2.90 (-4.38, -1.41) <.001
Age-adjusted                     Med 1.05 (-0.29, 2.40) .125 0.23 (-1.02, 1.49) .716
High 0.50 (-0.87, 1.87) .478 -0.06 (-1.35, 1.24) .929
Multivariable-adjusted        Med 0.98 (-0.34, 2.30) .145 0.70 (-0.52, 1.93) .260
High 0.87 (-0.48, 2.22) .207 0.29 (-0.98, 1.56) .658
PFOS
Unadjusted                        Med -1.22 (-2.76, 0.31) .118 -1.08 (-2.57, 0.41) .154
High -3.05 (-4.61, -1.49) <.001 -2.89 (-4.38, -1.40) <.001
Age-adjusted                     Med 0.66 (-0.70, 2.01) .344 0.10 (-1.16, 1.35) .877
High 1.15 (-0.31, 2.60) .123 1.50 (0.16, 2.85) .029
Multivariable-adjusted        Med 0.87 (-0.46, 2.20) .198 0.55 (-0.68, 1.77) .381
High 1.71 (0.28, 3.15) .019 1.49 (0.18, 2.80) .026
PFNA
Unadjusted                        Med 1.23 (-0.33, 2.78) .123 -0.56 (-2.05, 0.93) .463
High -0.04 (-1.60, 1.52) .958 -1.77 (-3.26, -0.28) .020
Age-adjusted                     Med 1.84 (.50, 3.18) .007 0.57 (-0.68, 1.82) .372
High 1.66 (0.30, 3.02) .017 0.58 (-0.70, 1.86) .372
Multivariable-adjusted        Med 1.85 (0.54, 3.17) .006 0.51 (-0.70, 1.72) .409
High 1.50 (0.16, 2.84) .028 0.10 (-1.14, 1.35) .871
PFHxS
Unadjusted                        Med -1.06 (-2.61, 0.50) .182 -2.13 (-3.61, -0.65) .005
High -2.42 (-3.97, -0.86) .002 -3.31 (-4.79, -1.83) <.001
Age-adjusted                     Med -0.19 (-1.54, 1.17) .788 -1.24 (-2.49, 0.02) .053
High -0.92 (-2.28, 0.44) .185 -0.91 (-2.19, 0.37) .162
Multivariable-adjusted        Med 0.25 (-1.08, 1.58) .708 -0.77 (-2.00, 0.45) .216
High -1.22 (-1.48, 1.24) .860 -0.24 (-1.50, 1.02) .706
N = 1450
Male Female
FEV1/FVC
*In all models, the reference category was the respective low PFAS tertile.  Med = Medium
Variables that were adjusted for: age, annual household income and race/ethnicity. 
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Discussion 
Overall, we observed a consistent statistically significant negative association between 
lung function and high PFAS exposure in females and some association in males in the 
unadjusted models. We did not observe an association that was consistently significant in the 
age-adjusted and multivariable adjusted models.  
One of the possible explanations of the above results could be that PFASs are endocrine 
disruptors (ED) and ED can impact males and females differently. Several published studies 
report gender dependent differences for PFASs related impacts, for example in a study by Byrne 
et al. (2018), a positive association between PFNA and PFOS with free T3 (triiodothyronine) was 
noted in females, conversely a negative association was seen with male free T3. In a separate 
study (Jain & Ducatman, 2019), PFNA and PFOA were positively associated with low-density 
lipoprotein cholesterol (LDL) and total cholesterol in obese males, however PFNA and PFDA 
(perfluorodecanoic acid) were positively associated with LDL and total cholesterol in obese 
females. 
The different associations between PFASs and lung function across genders noted in this 
study could be due to the differences in male and female lung function. The dissimilarities in 
lung structure and function between males and females start at the lung development prenatal 
phase (Carey et al., 2007; LoMauro & Aliverti, 2018). Female lungs mature sooner than males in 
the prenatal phase (Carey et al., 2007; LoMauro & Aliverti, 2018) and at birth, females have 
smaller lungs with fewer respiratory bronchioles (LoMauro & Aliverti, 2018). Males have bigger 
lungs than females after puberty meaning that males have a larger total number of alveoli thus 
they have a larger alveolar surface area (Carey et al., 2007; LoMauro & Aliverti, 2018). Male’s 
lung shapes are pyramidal whereas females have a more prismatic lung shape (LoMauro & 
PFAS EXPOSURE AND LUNG FUNCTION   23 
Aliverti, 2018) and recoil pressure of lungs differ due to the size of the lungs and the maximum 
descending forces. 
Other evidence also supports different impact of PFASs on male and female lung 
function. Qin et al. (2017) reported an association between PFAS exposure and impaired lung 
function in only male children. Although they believed that their sample size for females was too 
small, resulting in a significant association only for males (Qin et al., 2017). Sex hormones may 
impact the gender specific relationship between PFASs and lung function. Zhou et al. (2017) 
reported that in asthmatic children, PFASs had a negative association with testosterone levels 
and a positive association with estradiol levels.  
Relatively more studies are available on animals that tested the respiratory effects caused 
by PFASs. In a study by Ye et al. (2012), PFAS exposure was linked with neonatal mortality in 
mice, which was caused by under-developed lungs. In a separate study of mice pups, exposure to 
PFAS altered airway function, induced airway inflammation and increased the airway response 
(Qin et al., 2017). 
Our study was internally valid, because we addressed chance, confounding, and bias. 
Chance is not an explanation of our findings; our results consistently showed negative 
associations between different PFASs and FEV1, FVC, and FEV1/FVC in unadjusted models of 
females. For example, the B-value and 95% confidence interval (CI) of PFOA, showed a 
negative association in the unadjusted models for FEV1, -149.69 (-260.56, -38.82), p = .008. 
This negative association showed up consistently across the female lung function outcomes such 
as PFOA in unadjusted models with FEV1/FVC, and PFOS with FVC. Besides a valid 
association between PFASs exposure and lung function, other possible explanations for this 
finding could include bias and residual confounding. We adjusted for many known confounders, 
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except smoking. This was due to the complexity of methods utilized to collect smoking data in 
NHANES 2011 to 2012. However, there could still be unmeasured confounders that bias the 
observed association. One of those unmeasured confounders could be genetic/biological factors 
that cannot be measured quantitatively.  
As this was a cross sectional study, based on data from a national survey, selection bias 
was minimized by utilizing random sampling. To reduce information bias, the data collection 
team was provided extensive training to reduce errors in data collection, interviews, and data 
entry. Our study was externally valid and can be applied to the general U.S. population; both 
genders and different ethnicities, and a wide range of socio-economic strata, were taken into 
account. 
According to the well-defined Hill’s epidemiology criteria of causality (Crislip, 2010) 
exposure should precede outcome could not be met as NHANES is a cross sectional study. This 
study did have a dose response relationship between the exposure (PFASs: high compared to 
low) and the lung function. For almost all PFASs, in unadjusted models in females high exposure 
vs. low exposure was associated with poorer lung function. But among those PFASs that had 
significantly strong negative association with lung function, even the medium tertile of exposure 
in unadjusted models showed significant decrement in lung performance. This association was 
noted for PFNA in with FEV1, PFNA with FVC and PFHxS with FEV1/FVC ratio. Another 
causality criteria is consistency; we had consistent results for female lung function across all 
three types of spirometry measures in the unadjusted models; high exposure of PFNA was found 
to be significant in all three spirometry measures, high exposure in PFHxS was found to be 
significant in two spirometry measures (FEV1 & FEV1/FVC). Our study also had biological 
plausibility, as it known that PFASs exposure increases airway inflammation (Qin et al., 2017).  
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Strengths/Limitations 
One of the strengths of this study is that we used nationally representative data from a 
large, well known cross sectional study (NHANES). Some limitations of the study are not 
accounting for smoking as a confounder. 
Conclusion 
PFASs exposure was associated with decreased lung function in females in unadjusted 
models among a diverse population of participants from the NHANES 2011 to 2012 data. PFASs 
exposure is a public health concern due to its wide spread use in consumer products and health 
implications. More research is needed to explore association between PFASs exposure and lung 
function because the lungs are one of the main tissues where PFAS accumulate (Pérez et al., 
2013). 
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Appendix A: NHANES Spirometry Exclusion Questions 
• SPQ.010 Does SP [the participant] have a painful ear infection? 
• SPQ.020 Have you ever had eye surgery? (Do not include cosmetic surgery on the 
eyelid or skin around the eye.) 
• SPQ.030 Was the eye surgery in the last 3 months?  
• SPQ.040 Have you ever had open chest or abdominal surgery?  
• SPQ.050 Was the open chest or abdominal surgery in the last 3 months?  
• SPQ.060 Did you or anyone in your household have tuberculosis in the past year?  
• SPQ.070a Has a doctor or other health professional told you that you had an 
aneurysm?  
• SPQ.070b  Has a doctor or other health professional told you that you had a collapsed 
lung?  
• SPQ.070c  Has a doctor or other health professional told you that you had a detached 
retina? 
• SPQ.070d  Has a doctor or other health professional told you that you had a stroke?  
• SPQ.070e  Has a doctor or other health professional told you that you had a heart 
attack?  
• SPQ.080  Did this stroke happen in the last 3 months?  
• SPQ.090  Was your heart attack in the last 3 months?  
• SPQ.100  In the past month, have you coughed up blood?  
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Appendix B: NHANES Variable Names Table 
NHANES 
Variable Name Variable Description 
LBXPFOA Serum PFAS Level Perfluorooctanoic Acid (PFOA) 
LBXPFOS Serum PFAS Level Perfluorooctane Sulfonic Acid (PFOS) 
LBXPFNA Serum PFAS Level Perfluorononanoic Acid (PFNA) 
LBXPFHS Serum PFAS Level Perfluorohexane Sulfonic Acid (PFHxS) 
RIAGENDR Gender Gender of participant (Female or Male) 
RIDAGEYR Age Age of participant in years 
RIDRETH1 Race/Hispanic Origin Reported Race/Hispanic Origin of participants 
RaceEth3Groups Race/Hispanic Origin Recode of RIDRETH1 into three groups of Race/Hispanic origin 
INDHHIN2 Income Annual Household Income 
Income3lvl Income Recode of INDHHIN2 into three groups of income 
SPXNFEV1 FEV1 Test Baseline FEV 1 (mL) 
SPXNFVC FVC Test Baseline FVC (mL) 
FEV1_FVC FEV1/FVC Computed variable taking FEV1 diving that by FVC and multiplying it by 100 for a % 
Note: NHANES=National Health and Nutrition Examination Survey, PFAS=Perfluoroalkyl 
Substance 
Source: Centers for Disease Control and Prevention, National Center for Health Statistics (CDC 
NCHS), 2018. 
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Appendix C: Human Subjects Regulations Decisions Chart 
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Appendix D: List of Competencies Met in Integrative Learning Experience 
CEPH Foundational Competencies 
Evidence-based Approaches to Public Health 
2. Select quantitative and qualitative data collection methods appropriate for a given public health context 
3. Analyze quantitative and qualitative data using biostatistics, informatics, computer-based programming and 
software, as appropriate 
4. Interpret results of data analysis for public health research, policy or practice 
Communication 
19. Communicate audience-appropriate public health content, both in writing and through oral presentation 
 
WSU MPH Population Health Concentration Competencies 
3. Demonstrate the ability to contextualize and integrate knowledge of specific population health issues. 
4. Address diversity when evaluating population health issues related to improving population health, reducing 
disparities, or increasing equity. 
 
